Novastra Therapeutics is developing Next-Generation Immune Reprogramming Therapy (NIRT) using the OmniAntigen™ platform to rapidly reprogram the immune system. This platform enables near-patient manufacturing of immune-reprogramming doses in under three hours, facilitating same-day treatment for oncology applications.
Funding
Funding not disclosed
Founders
Product
Problem
Current immuno-oncology approaches often focus on single-target modulation, which can be insufficient for addressing complex tumor heterogeneity and immune escape mechanisms. The lengthy manufacturing times for traditional cell-based therapies also create significant logistical challenges and delays in patient treatment.
Solution
Novastra Therapeutics is developing Next-Generation Immune Reprogramming Therapy (NIRT) utilizing the OmniAntigen™ platform to enable rapid, system-level immune reprogramming. This platform converts patient- or pathogen-derived cells into immune-reprogramming doses within three hours, facilitating same-day, near-patient treatment. The process preserves a full antigen spectrum and drives DC-first, STING-sensitized activation, creating a combination-ready immune base layer. This approach is designed for oncology applications and holds potential for future immune-mediated diseases.
Target Audience
The primary target audience includes oncologists, clinical researchers, and pharmaceutical partners focused on developing combination therapies for solid tumors and other immune-mediated diseases.
Features
- OmniAntigen™ platform for rapid, system-level immune reprogramming.
- Near-patient manufacturing capability with a turnaround time of under three hours.
- Preservation of full antigen spectrum in generated doses.
- DC-first, STING-sensitized activation mechanism.
- Gene-editing-free process.
- Room-temperature stable dosing.
- Closed-system workflow for GMP-compliant manufacturing.
- Potential for decentralized scale-out and regional deployment.
- Applicable to oncology, infectious diseases, and immune-mediated disorders.